NASDAQ:APLS

Apellis Pharmaceuticals Stock Forecast

etoro logo Buy APLS
*Your capital is at risk
$41.03
+0 (+0%)
At Close: Jul 02, 2026
Add APLS to Watchlist?
Some Reasons Why To Add APLS:
  • +124.7% price growth over the last year
  • High gross margin of 90.1%
  • Lower volatility than the market (beta -0.25)

APLS Performance

FAQ

What is the symbol for Apellis Pharmaceuticals Inc. Stock and on which exchange is it traded?
The symbol for Apellis Pharmaceuticals Inc. is APLS and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Apellis Pharmaceuticals Inc. Stock?
Apellis Pharmaceuticals Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy Apellis Pharmaceuticals Inc. Stock?
Apellis Pharmaceuticals Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Apellis Pharmaceuticals Inc. Stock.

What's the current price of Apellis Pharmaceuticals Inc. Stock?
As of the end of day on the Jul 02, 2026, the price of an Apellis Pharmaceuticals Inc. (APLS) share was $41.03.

What is the 52-week high and low for Apellis Pharmaceuticals Inc. Stock?
The 52-week high for Apellis Pharmaceuticals Inc. Stock is $41.12 and the 52-week low is $16.83.

What is the market capitalization of Apellis Pharmaceuticals Inc. Stock?
As of the Jul 02, 2026, the market capitalization of Apellis Pharmaceuticals Inc. is 5.253B.

When is the next earnings date for Apellis Pharmaceuticals Inc.?
The upcoming earnings date for Apellis Pharmaceuticals Inc. is Jul 30, 2026.
Click to get the best stock tips daily for free!
ABOUT APELLIS PHARMACEUTICALS INC.
Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal ...
GOLDEN STAR
Ticker Change Signal Date
B
BXDC
$21.71
1.11% Jun 29
SRPT
$17.02
13.28% Jun 29
OSIS
$218.29
1.59% Jun 26
NMRK
$15.02
4.66% Jun 24
JLL
$299.78
9.23% Jun 24

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE